Clincosm LogoSign in Get a demo

The Expression of Serum Angiogenesis Marker in Patients Presenting With Hemoptysis

Sponsor
Samsung Medical Center (Other)
Overall Status
Completed
CT.gov ID
NCT01171768
Collaborator
(none)
52
Enrollment
1
Location
30
Duration (Months)
1.7
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2) are major mediators of angiogenesis and are induced by tissue inflammation and hypoxia. While elevated serum VEGF levels have been reported in inflammatory lung diseases, especially with hemoptysis, there was no study to evaluate the Ang-2 levels in lung inflammatory diseases according to the presence of hemoptysis, inflammatory biomarker and hypoxia.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    52 participants
    Observational Model:
    Case-Control
    Time Perspective:
    Prospective
    Official Title:
    The Expression of Serum Angiogenesis Marker in Patients Presenting With Hemoptysis
    Study Start Date :
    Jun 1, 2008
    Actual Study Completion Date :
    Dec 1, 2010

    Arms and Interventions

    Arm Intervention/Treatment
    patients with hemoptysis within 2 weeks
    patients without hemoptysis within 2 years

    Outcome Measures

    Primary Outcome Measures

    1. serum VEGF and Ang-2 level in lung inflammatory disease according to the presence of hemoptysis [up to 7 days after enrollment]

      We'll measure the serum VEFG and Ang-2 level of enrolled patients within a week from the moment that patients agree to enroll this study. Therefore, Comparison of the serum VEGF and Ang-2 level (measured within a week from enrollment) according to the presence of hemoptysis will be primary outcome.

    Secondary Outcome Measures

    1. to investigate association between angiogenesis factors and other factors such as inflammatory biomarker and hypoxia. [up to 7 days after enrollment]

      We'll measure the serum VEFG, Ang-2 level, and other factors such as inflammatory biomarkers and PaO2 of enrolled patients within a week from the moment that patients agree to enroll this study. Therefore, Investigating association between angiogensis factors and other factors such as inflammatory biomarker and hypoxia, which were measured within a week from enrollment, will be secondary outcome.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    20 Years to 90 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • patients visited Samsung Medical Center for the treatment of benign inflammatory disease such as bronchiectasis, aspergilloma, pneumonia and post-tuberculosis destroyed lung
    Exclusion Criteria:
    • patients with tumorous condition including lung cancer, vasculitis and the lung disease associated with collagen vascular disease on the point of enrollment

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Samsung Medical Center Seoul Korea, Republic of

    Sponsors and Collaborators

    • Samsung Medical Center

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    , ,
    ClinicalTrials.gov Identifier:
    NCT01171768
    Other Study ID Numbers:
    • 2008-05-043
    First Posted:
    Jul 28, 2010
    Last Update Posted:
    Jul 21, 2011
    Last Verified:
    Jul 1, 2011
    Keywords provided by , ,
    Vascular endothelial growth factor
    angiopoietin-2
    Additional relevant MeSH terms:
    Lung Diseases
    Hemoptysis

    Study Results

    No Results Posted as of Jul 21, 2011